Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer.

PURPOSE To assess observer-based vs. patient self-reported scoring of xerostomia after intensity-modulated radiotherapy (IMRT) of head-and-neck (HN) cancer. METHODS A total of 38 patients who had received IMRT for HN cancer underwent xerostomia evaluations 6 to 24 months after completion of therapy using three methods each time: (1) Grading by 3 observers according to the Radiotherapy Oncology Group/European Organization for Research and Therapy of Cancer (RTOG/EORTC) system; (2) patient self-reported validated xerostomia questionnaire (XQ); and (3) major salivary gland flow measurements. RESULTS The interobserver agreement regarding the RTOG/EORTC grades was moderate: kappa-coefficient 0.54 (95% CI=0.31-0.76). The correlations between the average RTOG/EORTC grades and the salivary flow rates were not statistically significant. A trend for significant correlation was observed between these grades and the percent (relative to the pretherapy) nonstimulated salivary flow rates (p=0.07), but not with the percent stimulated flow rates. Better correlations were found between grading made more than the median time (15 min) after the last liquid sipping and the nonstimulated (but not the stimulated) flows compared with grading made shortly after sipping. In contrast, significant correlations were found between the XQ scores and the nonstimulated (p<0.005) and the stimulated (p<0.005) salivary flow rates, as well as with the percentages of the corresponding pretherapy values (p=0.002 and 0.038, respectively). No significant correlation was found between the RTOG/EORTC grades and the XQ scores. The observer-based grades underestimated the severity of xerostomia compared with the patient self-reported scores. CONCLUSIONS Patient self-reported, rather than physician-assessed scores, should be the main end points in evaluating xerostomia.

[1]  J. Rieke,et al.  A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Levendag,et al.  Optimisation of conformal radiation therapy by intensity modulation: cancer of the larynx and salivary gland function. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  A Ralph Henderson,et al.  The bootstrap: a technique for data-driven statistics. Using computer-intensive analyses to explore experimental data. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[4]  K. Chao,et al.  Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine. , 2003, Seminars in oncology.

[5]  A. Rademaker,et al.  Effects of xerostomia on perception and performance of swallow function , 2001, Head & neck.

[6]  M. Martel,et al.  Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and noninvolved tissue sparing. , 1998, International journal of radiation oncology, biology, physics.

[7]  C. Terhaard,et al.  A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: implications for future trials. , 2005, International journal of radiation oncology, biology, physics.

[8]  R. Haddad,et al.  Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. , 2003, Seminars in oncology.

[9]  C. Leemans,et al.  Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy? , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  E. Pow,et al.  Salivary gland function and xerostomia in southern Chinese following radiotherapy for nasopharyngeal carcinoma , 2003, Clinical Oral Investigations.

[11]  D. Brizel,et al.  How should we measure and report radiotherapy-induced xerostomia? , 2003, Seminars in radiation oncology.

[12]  P. Fox,et al.  Subjective reports of xerostomia and objective measures of salivary gland performance. , 1987, Journal of the American Dental Association.

[13]  J. Dempsey,et al.  Late Xerostomia After Intensity-Modulated Radiation Therapy Versus Conventional Radiotherapy , 2005, American journal of clinical oncology.

[14]  S. Nill,et al.  Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. , 2004, International journal of radiation oncology, biology, physics.

[15]  P. Haddad,et al.  A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  J. Roh,et al.  Xerostomia following radiotherapy of the head and neck affects vocal function. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  LENT SOMA tables. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  D. Brizel,et al.  Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. , 2005, International journal of radiation oncology, biology, physics.

[19]  B. Vikram,et al.  Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Büntzel,et al.  Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. , 2002, Seminars in radiation oncology.

[21]  B. Ferguson Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer , 1994 .

[22]  R K Ten Haken,et al.  Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. , 1999, International journal of radiation oncology, biology, physics.

[23]  E. B. Butler,et al.  Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique. , 2003, International journal of radiation oncology, biology, physics.

[24]  B. Rhein,et al.  Stereotactic intensity modulated radiation therapy and inverse treatment planning for tumors of the head and neck region: clinical implementation of the step and shoot approach and first clinical results. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  A. Hinke,et al.  Randomized Phase III Trial of Postoperative Radiochemotherapy ± Amifostine in Head and Neck Cancer , 2003, Strahlentherapie und Onkologie.

[26]  G. Lockwood,et al.  A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.

[27]  R. Henriksson,et al.  Parotid gland function during and following radiotherapy of malignancies in the head and neck. A consecutive study of salivary flow and patient discomfort. , 1992, European journal of cancer.

[28]  P. Levendag,et al.  Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. , 2002, Seminars in oncology.

[29]  M. Puglisi,et al.  Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[30]  F. Fang,et al.  Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy , 2004, Cancer.

[31]  L. Dawson,et al.  Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.

[32]  Joseph O Deasy,et al.  Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[33]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[34]  P. Lambin,et al.  Preservation of parotid function with uncomplicated conformal radiotherapy. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[35]  C. Tsien,et al.  Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. , 2005, International journal of radiation oncology, biology, physics.

[36]  Joseph O Deasy,et al.  Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. , 2004, International journal of radiation oncology, biology, physics.

[37]  Margie Hunt,et al.  Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. , 2006, International journal of radiation oncology, biology, physics.

[38]  G. Lockwood,et al.  Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. , 2005, International journal of radiation oncology, biology, physics.

[39]  P. Anné Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. , 2002, Seminars in oncology.

[40]  E. B. Butler,et al.  Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. , 2004, International journal of radiation oncology, biology, physics.

[41]  P. Xia,et al.  Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. , 2001, International journal of radiation oncology, biology, physics.

[42]  G. Calais,et al.  Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. , 2002, Seminars in oncology.

[43]  L. Dawson,et al.  Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. , 2003, International journal of radiation oncology, biology, physics.

[44]  D. Robinson,et al.  Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[45]  Yasumasa Nishimura,et al.  Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT. , 2005, Japanese journal of clinical oncology.

[46]  T. Whelan,et al.  A Phase I-II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[47]  Heikki Joensuu,et al.  Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[48]  D. Brizel,et al.  The prevention and treatment of radiotherapy - induced xerostomia. , 2003, Seminars in radiation oncology.

[49]  A. Monnier,et al.  Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. , 2006, International journal of radiation oncology, biology, physics.

[50]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[51]  J. Schulte‐Mönting,et al.  Different Saliva Substitutes for Treatment of Xerostomia Following Radiotherapy , 2005, Strahlentherapie und Onkologie.

[52]  C. Perez,et al.  Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[53]  Yaoh-Shiang Lin,et al.  Parotid gland-sparing 3-dimensional conformal radiotherapy results in less severe dry mouth in nasopharyngeal cancer patients: a dosimetric and clinical comparison with conventional radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[54]  S. Leung,et al.  Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. , 2004, International journal of radiation oncology, biology, physics.

[55]  Fabrice Denis,et al.  Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. , 2003, International journal of radiation oncology, biology, physics.

[56]  P. Xia,et al.  Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. , 2000, International journal of radiation oncology, biology, physics.

[57]  P. Levendag,et al.  Patients with head and neck cancer cured by radiation therapy: A survey of the dry mouth syndrome in long‐term survivors , 2002, Head & neck.

[58]  J. Deasy,et al.  A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. , 2001, International journal of radiation oncology, biology, physics.

[59]  P. Xia,et al.  Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. , 2003, International journal of radiation oncology, biology, physics.

[60]  Radhe Mohan,et al.  Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results. , 2004, International journal of radiation oncology, biology, physics.

[61]  A. Hinke,et al.  Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? , 2003, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[62]  G. Field,et al.  Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[63]  E. B. Butler,et al.  Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. , 1999, International journal of radiation oncology, biology, physics.

[64]  Robert L. White,et al.  Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09. , 2003, International journal of radiation oncology, biology, physics.

[65]  D L McShan,et al.  Is uniform target dose possible in IMRT plans in the head and neck? , 2002, International journal of radiation oncology, biology, physics.